Does Zetia Decrease LDL?
Yes, Zetia (ezetimibe) effectively decreases LDL cholesterol by approximately 18-20% when used as monotherapy and provides an additional 25% incremental reduction when combined with statin therapy. 12
Mechanism and FDA-Approved Efficacy
Ezetimibe works by inhibiting the NPC1L1 protein, which reduces cholesterol absorption in the small intestine 1. The FDA label confirms the following LDL-C reductions 22:
- Monotherapy: 18-20% reduction in LDL-C
- Combination with statins: Additional 25% incremental reduction beyond statin alone
- Specific combinations show:
- With simvastatin: 46-58% total LDL-C reduction (depending on statin dose)
- With pravastatin: 34-42% total LDL-C reduction
- With lovastatin: 34-46% total LDL-C reduction
Clinical Outcomes Beyond LDL Lowering
Importantly, ezetimibe not only lowers LDL-C but also reduces cardiovascular events. The IMPROVE-IT trial demonstrated that adding ezetimibe to moderate-intensity statin therapy in patients with recent acute coronary syndrome resulted in both incremental LDL-C lowering AND reduced cardiovascular death, nonfatal MI, unstable angina requiring hospitalization, coronary revascularization, or nonfatal stroke over a median 6-year follow-up 11. The SHARP trial similarly showed reduced major ASCVD events in patients with chronic kidney disease 1.
Guideline-Recommended Use
The 2022 ACC Expert Consensus recommends ezetimibe as the first-line add-on therapy when patients don't achieve LDL-C goals on maximally tolerated statin therapy 11. Multiple international guidelines (ESC/EAS 2019, Canadian Cardiovascular Society 2021) recommend adding ezetimibe when LDL goals aren't met with maximum tolerated statin doses 333.
Additional Lipid Effects
Beyond LDL-C, ezetimibe reduces:
- Total cholesterol: 12-13%
- Apolipoprotein B: 11-15%
- Non-HDL cholesterol: 15-30% (especially when combined with fenofibrate)
- Triglycerides: 5-11% (median reduction)
- Remnant-like particle cholesterol: 21% 4
- Oxidized LDL: Significant reduction when combined with statins 5
It also modestly increases HDL-C by 3-5% 22.
Safety Profile
Ezetimibe is generally well tolerated with a favorable safety profile 1. Common side effects include upper respiratory tract infection, diarrhea, arthralgia, and sinusitis when used as monotherapy 1.
Key precautions:
- Not recommended in moderate/severe hepatic impairment
- Monitor liver transaminases when combined with statins
- Rare cases of myopathy/rhabdomyolysis reported (increased risk with statin combination)
- Avoid in pregnancy and breastfeeding
- Take 2 hours before or 4 hours after bile acid sequestrants due to reduced bioavailability 12
Clinical Application
For patients with ASCVD or very high cardiovascular risk: Add ezetimibe when LDL-C remains ≥70 mg/dL despite maximally tolerated statin therapy 333. The benefit is consistent regardless of baseline LDL-C level—even patients with baseline LDL-C <70 mg/dL showed cardiovascular benefit from adding ezetimibe in IMPROVE-IT 6.
The drug is available as a generic, making it cost-effective compared to PCSK9 inhibitors 1.